Products for Research Use Only
RegisterLogin

SPR719

CAT: 0804-HY-12930-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-12930-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
SPR719 (VXc-486) is an orally active gyrase B inhibitor, with bactericidal activity. SPR719 potently inhibits multiple agent-sensitive isolates and drug-resistant isolates of Mycobacterium tuberculosis, with MICs of 0.03 to 0.30 μg/ml and 0.08 to 5.48 μg/ml, respectively. SPR719 is promising for research of lung disease caused by non-tuberculous mycobacteria (NTM) [1][2][3][4].
CAS Number
1384984-18-2
Product Name Alternative
VXc-486
UNSPSC
12352005
Target
Bacterial; Topoisomerase
Type
Reference compound
Related Pathways
Anti-infection; Cell Cycle/DNA Damage
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/vxc-486.html
Purity
99.39
Solubility
DMSO : 20 mg/mL (ultrasonic; adjust pH to 2 with HCl)
Smiles
O=C(NC1=NC2=CC(C3=CN=C(C(C)(O)C)N=C3)=C(F)C([C@@H]4OCCC4)=C2N1)NCC
Molecular Formula
C21H25FN6O3
Molecular Weight
428.46
References & Citations
[1]Locher CP, et al. A novel inhibitor of gyrase B is a potent drug candidate for treatment of tuberculosis and nontuberculosis mycobacterial infections. Antimicrob Agents Chemother. 2015 Mar;59 (3) :1455-65.|[2]Pidot SJ, et al. In vitro activity of SPR719 against Mycobacterium ulcerans, Mycobacterium marinum and Mycobacterium chimaera. PLoS Negl Trop Dis. 2021 Jul 26;15 (7) :e0009636.|[3]Aragaw WW, et al. In Vitro Resistance against DNA Gyrase Inhibitor SPR719 in Mycobacterium avium and Mycobacterium abscessus. Microbiol Spectr. 2022 Feb 23;10 (1) :e0132121.|[4]Cotroneo N, et al. In vitro activity and in vivo efficacy against non-tuberculous mycobacteria of SPR719, the active moiety of the novel oral benzimidazole prodrug SPR720[J]. bioRxiv, 2022: 2022.12. 08.519697.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Related Products

CatalogName
HY-P1649-01SPR741
HY-P1649ASPR741 (TFA)
HY-P1649B-01SPR741 (acetate)
HY-152220SPR39
HY-152224SPR41
HY-150506SPR7
HY-RS13714SPRR1B Human Pre-designed siRNA Set A
HY-RS13713SPRR1A Human Pre-designed siRNA Set A
HY-RS13721SPRY1 Human Pre-designed siRNA Set A
HY-RS28284Spry1 Rat Pre-designed siRNA Set A

Alternative Products

CatalogName
JFC98418-01SPR719
A21471-25SPR719 (VXc-486) 25mg
A21471-50SPR719 (VXc-486) 50mg
A21471-100SPR719 (VXc-486) 100mg

Popular Products